Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content

January 2015, Volume 22, Issue 1

In the first edition of the EJHP for 2015 you can find a review of the experiences of patients who use home based parenteral nutrition and orginal articles from Italy and the UK looking at the economic and patient factors influencing the use of antifungals within hospitals.

Reviewing the availble literature on patient expeirence of homebased parenteral nutrition Wong et al concludes that there is still plenty to be investigated and further qualitative research in the non clinical outcomes for these patients. Whilst there is data on mortality and clinical outcomes there is more work to be done regarding quality of life indicators.

The use of  anidulafungin in intensive care units (ICUs), substituting caspofungin and liposomal amphotericin B where appropriate was invesitgated by colleagues in Italy. In their hosptial in Turin they performed a retrospective analysis regarding the potential econmonic cost saving. They estimated that if anidulafungin was used instead of caspofunin and/or liposomal amphotericin B up to €80 047 could be saved by the hospital.

On the same antifungal theme their use forlife-limiting illnesses in England was investigated by Stephens et al. Using patient level information from the NHS database they found that fluconazole was the most common antifungal used (75% of admissions) and the various patterns cannot be simply explained by disease, comorbidities, contraindications, guidelines or systematic bias against particular groups of patients. They concluded by highlighting the importance for antifungal stewardship in European Hospitals.

×